354997-99-2Relevant articles and documents
XPA INHIBITOR COMPOUNDS AND THEIR USE
-
Page/Page column 46-48, (2019/04/16)
The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.
KU INHIBITORS AND THEIR USE
-
Page/Page column 39, (2017/12/29)
The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.
Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists
Huang, Huang,Yu, Ying,Gao, Zhenting,Zhang, Yong,Li, Chenjing,Xu, Xing,Jin, Hui,Yan, Wenzhong,Ma, Ruoqun,Zhu, Jin,Shen, Xu,Jiang, Hualiang,Chen, Lili,Li, Jian
, p. 7037 - 7053 (2013/01/14)
LBVS of 12480 in-house compounds, followed by HTRF assay, resulted in one nonsteroidal compound (11) with antagonistic activity against FXR (69.01 ± 11.75 μM). On the basis of 11, 26 new derivatives (12a-z) were designed and synthesized accordingly. Five
